Medical device company Cardiovascular Systems (CSI) has commenced a voluntary recall of its WIRION Embolic Protection Systems (WIRION).

The unused WRN-D6 models of the WIRION device are being recalled due to receipt of complaints regarding filter breakage at the time of retrieval.

The company stated that the filter breakage may cause device embolism as well as additional intervention.

All affected healthcare facilities were informed to stop using and return the unused WIRION devices to the company.

CSI has also notified the US Food and Drug Administration (FDA) regarding the voluntary recall.

The company has received nine filter breakage complaints so far and plans to recall all the devices which are currently in customer inventory.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Between 22 March and 15 November, approximately 697 devices were distributed in the US.

WIRION is a rapid exchange, pre-loaded filter, which is used as an embolic protection system for removing embolic material (thrombus/debris) while performing atherectomy in calcified lesions of the lower extremities.

The single-use product is provided sterile and can be used with commercially available 0.014in guide wires.

In March, CSI acquired a portfolio of peripheral support catheters from WavePoint Medical.

These catheters are used during peripheral vascular intervention (PVI) procedures for guidewire support to aid in lesion crossing and for guidewire exchanges.

Physicians use support catheters in about 50% of PVIs, mostly in complex and below-the-knee interventions.

CSI expects to introduce the acquired catheters as its new ViperCross line in the first half of its fiscal year, which ends on 30 June 2022.